Boston Scientific Corp [BSX] stock is trading at $104.58, up 0.28%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BSX shares have gain 3.17% over the last week, with a monthly amount drifted -1.50%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Boston Scientific Corp [NYSE: BSX] stock has seen the most recent analyst activity on June 16, 2025, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $118. Previously, Needham upgraded its rating to Buy on April 16, 2025, and kept the price target unchanged to $113. On January 10, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $108 on the stock. Needham downgraded its rating to a Hold. Goldman initiated its recommendation with a Buy and recommended $90 as its price target on May 30, 2024. Mizuho upgraded its rating to Buy for this stock on February 01, 2024, and upped its price target to $80. In a note dated July 19, 2023, Robert W. Baird initiated an Outperform rating and provided a target price of $59 on this stock.
Boston Scientific Corp [BSX] stock has fluctuated between $71.88 and $107.17 over the past year. Currently, Wall Street analysts expect the stock to reach $117.33 within the next 12 months. Boston Scientific Corp [NYSE: BSX] shares were valued at $104.58 at the most recent close of the market. An investor can expect a potential return of 12.19% based on the average BSX price forecast.
Analyzing the BSX fundamentals
Boston Scientific Corp [NYSE:BSX] reported sales of 17.55B for the trailing twelve months, which represents a growth of 20.93%. Gross Profit Margin for this corporation currently stands at 0.67% with Operating Profit Margin at 0.18%, Pretax Profit Margin comes in at 0.14%, and Net Profit Margin reading is 0.12%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.1 and Total Capital is 0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.53.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 104.09 points at the first support level, and at 103.61 for the second support level. However, for the 1st resistance point, the stock is sitting at 105.13, and for the 2nd resistance point, it is at 105.69.
Ratios To Look Out For
For context, Boston Scientific Corp’s Current Ratio is 1.45. As well, the Quick Ratio is 0.88, while the Cash Ratio is 0.14. Considering the valuation of this stock, the price to sales ratio is 8.81, the price to book ratio is 6.96 and price to earnings (TTM) ratio is 76.63.
Transactions by insiders
Recent insider trading involved Fitzgerald Joseph Michael, EVP & Group Pres, Cardiology, that happened on Jun 04 ’25 when 56372.0 shares were sold. Officer, JOSEPH M FITZGERALD completed a deal on Jun 04 ’25 to buy 56372.0 shares. Meanwhile, Chairman, President & CEO Mahoney Michael F sold 0.16 million shares on Jun 02 ’25.
